Acute myeloid leukaemia (AML)


Our goal
Raised so far

Acute myeloid leukaemia (AML) is a highly fatal blood cancer in adults and children.

The median 5-year survival for adult AML is less than 30% and one-third of children with AML relapse due to treatment resistance, with only 30% of relapsed patients surviving their disease.

Donate to this project

Survival starts with science. Your donation will keep this project going.

Donate now

Resistance to treatment is thus a major challenge within the AML field and there is an urgent need to develop more effective and safer treatments for AML.

Altered metabolism plays a key role in cancer progression and resistance to treatment, making it an attractive therapeutic target. This research team recently showed that acute myeloid leukaemia (AML) cells are addicted to a metabolic enzyme called NAMPT, and that blocking NAMPT kills AML cells and also makes them more sensitive to standard of care drugs. By adding a newly developed NAMPT inhibitor to standard of care treatment, this project can pave the way towards a more effective treatment of poor outcome adult and paediatric AML. 

*Learn about Cancer Australia's Priority-driven Collaborative Cancer Research Scheme.


Dr Klaartje Somers


Children’s Cancer Institute

The Kids' Cancer Project Funding

$181,559 January 2023 to December 2025

Cancer Australia PdCCRS


Total Funding


Dr Klaartje Somers
Dr Klaartje Somers

Project partners

Trademark Group of Companies
Acute myeloid leukaemia (AML)